NCPC(SH:600812) Ge Long Hui·2025-09-02 11:13Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1 - The injectable vancomycin hydrochloride is effective against infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The product can also be administered orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] - The approval of this product enhances the company's product structure in the field of anti-infection, building on its existing product, Vanxun (injectable desacetyl vancomycin) [1]